Skip to main content
SpringerLink
Log in

Protein Therapeutic: Production, Application, and Future Scenario

  • Chapter
  • First Online:
Metabolic Engineering for Bioactive Compounds

Abstract

The demands for recombinant therapeutic proteins are escalating rapidly over the past two decades because of its effectiveness in treating human diseases that are uncurable. To meet the increasing demand, there is continuous need to enhance the existing expression systems, furthermore building up an attractive strategy to confront the therapeutic protein demands. Nowadays, human cell line has come up as a novel and effective strategy to generate therapeutic proteins since this expression framework possesses the machinery to modify the recombinant proteins to its final form (posttranslational modifications) analogous to those present human proteins. In addition human cell lines also decrease the possible immunogenicity against non-human antigenic determinants. Therefore, the present chapter discusses about how recombinant proteins with therapeutic properties can be in mammalian cells and their application, and finally we will talk how new innovations might add to the further advancement and generation of therapeutic proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adam E, Sarrazin S, Landolfi C, Motte V, Lortat-Jacob H, Lassalle P, Delehedde M (2008) Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor. Biochem Biophys Res Commun 369:297–302. doi:10.1016/j.bbrc.2008.01.141

    Article  CAS  PubMed  Google Scholar 

  • Akash MSH, Rehman K, Chen S (2013) IL-1Ra and its delivery strategies: inserting the association in perspective. Pharm Res 30:2951–2966. doi:10.1007/s11095-013-1118-0

    Article  CAS  PubMed  Google Scholar 

  • Akash MSH, Shen Q, Rehman K, TARIQ M, Chen S (2015) Development of therapeutic proteins: advances and challenges. Turk J Biol 39:1–16. doi:10.3906/biy-1411-8

    Article  Google Scholar 

  • Akash MSH, Shen Q, Rehman K, Chen S (2012) Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 101:1647–1658. doi:10.3906/biy-1411-8

    Article  CAS  PubMed  Google Scholar 

  • Backliwal G, Hildinger M, Hasija V, Wurm FM (2008) High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 99:721–727. doi:10.1002/bit.21596

    Article  CAS  PubMed  Google Scholar 

  • Baldi L, Hacker DL, Adam M, Wurm FM (2007) Recombinant protein production by large scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29:677–684. doi:10.1007/s10529-006-9297

    Article  CAS  PubMed  Google Scholar 

  • Belin V, Rousselle P (2006) Production of a recombinantly expressed laminin fragment by HEK293-EBNA cells cultured in suspension in a dialysis-based bioreactor. Prot Expr Purif 48:43–48. doi:10.1016/j.pep.2006.02.014

    Article  CAS  Google Scholar 

  • Butler M (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 68:283–291. doi:10.1007/s00253-005-1980-8

    Article  CAS  PubMed  Google Scholar 

  • Campos-Neto A, Rodrigues-Junior V, Pedral-Sampaio DB, Netto EM, Ovendale PJ, Coler RN, Skeiky YA, Badaro R, Reed SG (2001) Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. Tuberculosis (Edinb) 81:353–358. doi:10.1054/tube.2001.0311

    Article  CAS  Google Scholar 

  • Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 17:1261–1269. doi:10.1016/j.yexcr.2011.02.013

    Article  Google Scholar 

  • Cho MS, Yee H, Chan S (2002) Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci 9:631–638. doi:10.1159/000067294

    Article  CAS  PubMed  Google Scholar 

  • Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062–1068. doi:10.1136/ard.2003.016014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T (2002) Efficacy of recombinant human erythropoietin in critically III patients: a randomized controlled trial. JAMA 288:2827–2835. doi:10.1001/jama.288.22.2827

    Article  CAS  PubMed  Google Scholar 

  • Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, Wurm FM (2004) Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng 87:537–545. doi:10.1002/bit.20161

    Article  CAS  PubMed  Google Scholar 

  • Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HWG, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 119:3024–3030. doi:10.1182/blood-2011-08-367813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Durocher Y, Perret S, Kamen A (2002) High level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9. doi:10.1093/nar/30.2.e9

    Article  PubMed  PubMed Central  Google Scholar 

  • Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P (1997) A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329–1335. doi:10.1056/NEJM199711063371901

    Article  CAS  PubMed  Google Scholar 

  • Ferrer-Miralles N, Saccardo P, Corchero JL, Xu Z, García-Fruitós E (2015) General introduction: recombinant protein production and purification of insoluble proteins. Methods Mol Biol 1258:1–24. doi:10.1007/978-1-4939-2205-5_1

    Article  CAS  PubMed  Google Scholar 

  • Figueroa B Jr, Ailor E, Osborne D, Hardwick JM, Reff M, Betenbaugh MJ (2007) Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells. Biotechnol Bioeng 97:877–892. doi:10.1002/bit.21222

    Article  CAS  PubMed  Google Scholar 

  • Fischer S, Charara N, Gerber A, Wolfel J, Schiedner G, Voedisch B, Geisse S (2012) Transient recombinant protein expression in a human amniocytecell line: the CAP-T1 cell system. Biotechnol Bioeng 109:2250–2261. doi:10.1002/bit.24514

    Article  CAS  PubMed  Google Scholar 

  • FDA (2015) Novel drug approvals for 2015. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302

  • Geisse S (2009) Reflections on more than 10 years of TGE approaches. Protein Expr Purif 64:99–107. doi:10.1016/j.pep.2008.10.017

    Article  CAS  PubMed  Google Scholar 

  • Girard P, Derouazi M, Baumgartner G, Bourgeois M, Jordan M, Jacko B, Wurm FM (2002) 100-liter transient transfection. Cytotechnology 38:15–21. doi:10.1023/A:1021173124640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Houdebine LM (2009) Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 32:107–121. doi:10.1016/j.cimid.2007.11.005

    Article  PubMed  Google Scholar 

  • Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324:1186–1194. doi:10.1056/NEJM199104253241707

    Article  CAS  PubMed  Google Scholar 

  • Jones D, Kroos N, Anema R, Montfort B, Vooys A, Kraats S, Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, Berkel P, Opstelten D, Logtenberg T, Bout A (2003) High-level expression of recombinant IgG in the human cell line PER C6. Biotechnol Prog 19:163–168. doi:10.1021/bp025574h

    Article  CAS  PubMed  Google Scholar 

  • Kruif J, Kramer A, Nijhuis R, Zande V, Blanken R, Clements C, Visser T, Keehnen R, Hartog M, Throsby M, Logtenberg T (2010) Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 106:741–750. doi:10.1002/bit.22763

    Article  PubMed  Google Scholar 

  • Lander ES, Linton LM, Birren B, Nusbaum C et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921. doi:10.1038/35057062

    Article  CAS  PubMed  Google Scholar 

  • Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:21–39. doi:10.1038/nrd2399

    Article  CAS  PubMed  Google Scholar 

  • MacKenzie IZ, Bichler J, Mason GC, Lunan CB, Stewart P, Al-Azzawi F, De Bono M, Watson N, Andresen I (2004) Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 117:154–161. doi:10.1016/j.ejogrb.2004.03.009

    Article  CAS  PubMed  Google Scholar 

  • Mahmood I, Green MD (2005) Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44:331–347. doi:10.2165/00003088-200544040-00001

    Article  CAS  PubMed  Google Scholar 

  • Matasci M, Hacker DL, Baldi L, Wurm FM (2008) Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects. Drug Discov Today Technol 5:e37–e42. doi:10.1016/j.ddtec.2008.12.003

    Article  PubMed  Google Scholar 

  • Mei B, Chen Y, Chen J, Pan CQ, Murphy JE (2006) Expression of human coagulation factor VIII in a human hybrid cell line HKB11. Mol Biotechnol 34:165–178. doi:10.1385/MB:34:2:165

    Article  CAS  PubMed  Google Scholar 

  • Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, JM G, Subramanyam B, Fournel MA, Pierce GF, Murphy JE (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 116:270–279. doi:10.1182/blood-2009-11-254755

    Article  CAS  PubMed  Google Scholar 

  • Ohya S, Matsuda T (2005) Poly (N-isopropylacrylamide) (PNIPAM)—grafted gelatin as thermo responsive three-dimensional artificial extracellular matrix: molecular and formulation parameters vs. cell proliferation potential. J Biomater Sci Polym Ed 16:809–827. doi:10.1163/1568562054255736

    Article  CAS  PubMed  Google Scholar 

  • Pennisi E (2003) Bioinformatics Gene counters struggle to get the right answers. Science 301:1040–1041. doi:10.1126/science.301.5636.1040

    Article  CAS  PubMed  Google Scholar 

  • Picanco-Castro V, Biaggio RT, Cova DT, Swiech K (2013) Production of recombinant therapeutic protein in human cells: current achievements and future perspectives. Protein Pept Lett 20:1373–1381. doi:10.2174/092986652012131112130322

    Article  CAS  PubMed  Google Scholar 

  • Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, Velasco J, Whaley K, Zeitlin L, Garger SJ, White E, Bai Y, Haydon H, Bratcher B (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 8:638–654. doi:10.1111/j.1467-7652.2009.00495

    Article  CAS  PubMed  Google Scholar 

  • Rader RA (2008) Redefining biopharmaceutical. Nat Biotechnol 26:743–751. doi:10.1038/nbt0708-743

    Article  CAS  PubMed  Google Scholar 

  • Ross D, Brown T, Harper R, Pamarthi M, Nixon J, Bromirski J, Li CM, Ghali R, Xie H, Medvedeff G, Li H, Scuderi P, Arora V, Hunt J, Barnett T (2012) Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J Biotechnol 162:262–723. doi:10.1016/j.jbiotec.2012.09.018

    Article  CAS  PubMed  Google Scholar 

  • Rosser MP, Xia W, Hartsell S, McCaman M, Zhu Y, Wang S, Harvey S, Bringmann P, Cobb RR (2005) Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression system. Protein Expr Purif 40:237–243. doi:10.1016/j.pep.2004.07.015

    Article  CAS  PubMed  Google Scholar 

  • Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL (2001) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98:3600–3606. doi:http://dx.doi.org/10.1182/blood-2002-07-2080

    Article  CAS  PubMed  Google Scholar 

  • Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208. doi:10.1200/JCO.2004.10.182

    Article  CAS  PubMed  Google Scholar 

  • Schiedner G, Hertel S, Bialek C, Kewes H, Waschütza G, Volpers C (2008) Efficient and reproducible generation of high expressing stable human cell lines without need for antibiotic selection. BMC Biotechnol 8:13. doi:10.1186/1472-6750-8-13

    Article  PubMed  PubMed Central  Google Scholar 

  • Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G (2000) Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The Prosta Scint Imaging Centers. Urology 56:988–993. doi:10.1016/S0090-4295(00)00824-4

    Article  CAS  PubMed  Google Scholar 

  • Sun X, Goh PE, Wong KTK, Mori T, Yap MGS (2006) Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension. Biotechnol Lett 28:843–848. doi:10.1007/s10529-006-9010-1

    Article  CAS  PubMed  Google Scholar 

  • Swiech K, Picanço-Castro V, Covas DT (2012) Human cells: new platform for recombinant therapeutic protein production. Protein Expr Purif 84:147–153. doi:10.1016/j.pep.2012.04.023

    Article  CAS  PubMed  Google Scholar 

  • Tang L, Leong L, Sim D, Ho E, JM G, Schneider D, Feldman RI, Monteclaro F, Jiang H, Murphy JE (2013) von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 19:539–545. doi:10.1111/hae.12116

    Article  CAS  PubMed  Google Scholar 

  • Tchoudakova A, Hensel F, Murillo A, Eng B, Foley M, Smith L, Schoenen F, Hildebrand A, Kelter AR, Ilag LL, Vollmers HP, Brandlein S, McIninch J, Chon J, Lee G, Cacciuttolo M (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs 1:163–171. doi:10.4161/mabs.1.2.7945

    Article  PubMed  PubMed Central  Google Scholar 

  • Van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004) Long term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804–810. doi:10.1002/hep.20128

    Article  PubMed  Google Scholar 

  • Venter JC, Adams MD, Myers EW, Li PW et al (2001) The sequence of the human genome. Science 291:1304–1351. doi:10.1126/science.1058040

    Article  CAS  PubMed  Google Scholar 

  • Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges world. J Biol Chem 26(3):73–92. doi:10.4331/wjbc.v3.i4.73

    Google Scholar 

  • Wajih N, Owen J, Wallin R (2008) Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shrna transfection. Thromb Res 122:405–410. doi:10.1016/j.thromres.2007.11.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walsh G (2010) Biopharmaceutical benchmarks. Nat Biotechnol 28:917–924. doi:10.1038/nbt0910-917

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463. doi:10.1200/JCO.2002.11.076

    Article  CAS  PubMed  Google Scholar 

  • Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398. doi:10.1038/nbt1026

    Article  CAS  PubMed  Google Scholar 

  • Zhang J (2010) In: Richard HB, Davies JE, Demain AL (eds) Manual of industrial microbiology and biotechnology. ASM Press, Washington, DC, pp 157–178. doi:10.1128/9781555816827

    Google Scholar 

  • Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30:1158–1170. doi:10.1016/j.biotechadv.2011.08.022

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

R.C. is supported by University Research Scholarship of M. D. University, Rohtak, India.

Author information

Authors and Affiliations

  1. Centre for Biotechnology Maharshi Dayanand University, Rohtak, 124001, Haryana, India

    Renu Chaudhary, Meenakshi Balhara & Anil Kumar Chhillar

Authors
  1. Renu Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meenakshi Balhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil Kumar Chhillar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Kumar Chhillar .

Editor information

Editors and Affiliations

  1. Microbial Biotechnology and Genomics, CSIR - Institute of Genomics and Integrative Biology (IGIB), New Delhi, India

    Vipin Chandra Kalia

  2. Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Solan, Himachal Pradesh, India

    Adesh Kumar Saini

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Chaudhary, R., Balhara, M., Chhillar, A.K. (2017). Protein Therapeutic: Production, Application, and Future Scenario. In: Kalia, V., Saini, A. (eds) Metabolic Engineering for Bioactive Compounds. Springer, Singapore. https://doi.org/10.1007/978-981-10-5511-9_4

Download citation

Publish with us

Policies and ethics

Search

Navigation